Successfully combating HAIs has become a significant and actionable financial opportunity for U.S. hospitals today.
In January 2015, CMA began measuring C. difficile and MRSA infections as key performance standards in Value Based Purchasing (VBP) and Hospital Acquired Condition (HAC) Reduction Programs. By 2017, 5% of hospital inpatient Medicare reimbursement will depend upon performance in these programs. Hospitals are now scored on items like patient satisfaction (HCAHPS) and their infection rate.
These scores directly impact reimbursement, potentially costing millions of dollars.
How much could you save?
Request your personalized in-person ROI analysis to find out how much extra Medicare funding you could unlock by decreasing you infection rates with Xenex Germ-Zapping Robots™.